# Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

> **NCT00891137** · PHASE1 · COMPLETED · sponsor: **Cellerant Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Multiple Myeloma
- Plasma Cell Neoplasm
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** human myeloid progenitor cells

## Key facts

- **NCT ID:** NCT00891137
- **Lead sponsor:** Cellerant Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891137, "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00891137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*